Objective. Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to gain insight into which outcome measure, if any, was best able to discern differences among treatment groups.
We recently examined the data from a large, multicenter, randomized, double-blind, placebocontrolled trial of abatacept in patients with lupus nephritis to evaluate the performance of several definitions of complete response (CR) (1) . Our analysis highlighted that there was great variation in the ability of the different definitions of CR to discriminate between treatment groups. Our work provided a compelling demonstration that, in some instances, the choice of outcome measure, rather than the actual data, may determine whether an experimental agent is perceived as effective or ineffective. However, because the analysis was limited to various definitions of CR, it did not address whether CR should be the preferred outcome measure when testing novel therapies for patients with active lupus nephritis, or whether other outcome measures could discriminate more successfully among treatment groups.
Previous lupus nephritis trials have used a wide range of primary outcome measures. The landmark trial of pulse cyclophosphamide conducted at the National Institutes of Health focused on the frequency of endstage renal disease (2) . The Euro-Lupus Nephritis Trial of mini-pulse cyclophosphamide therapy also relied on treatment failure as the primary outcome measure, although the definition of treatment failure used was broader than just end-stage renal disease (3) . More recently, trials of new agents have shifted the paradigm from frequency of treatment failure to measures of treatment success, permitting an earlier assessment of response (1, 4, 5) . Even in these studies, however, the choice of primary outcome has differed, with some studies relying on CR rates, some on total response rates (CR plus partial response [PR]), and some on time to response. Furthermore, whereas some studies examined the primary end point at 6 months, others examined the primary end point at 12 months.
This study was undertaken to assess the relative discriminatory capability of a number of potential outcome measures for use in lupus nephritis clinical trials. To accomplish this goal, we applied a diverse set of outcome measures to the same clinical data (1).
PATIENTS AND METHODS
Study design. The trial was a 12-month, phase II/III, multicenter, randomized, double-blind, controlled trial of abatacept versus placebo, on a background of standard-of-care treatment with mycophenolate mofetil (MMF) and glucocorticoids, in patients with active lupus nephritis. The study design has been described in detail previously (1) . Briefly, 300 patients who met, either sequentially or coincidentally, 4 of the 11 Figure 1 . Complete response (CR) rates, major clinical response (MCR) rates, and total response (CR plus partial response [PR]) rates at week 52 (A) and week 24 (B) in each abatacept treatment group compared with the standard-of-care placebo control group. For the treatment groups, one group received abatacept infusions on days 1, 15, and 29, and every 28 days thereafter for 12 months at a fixed, weight-tiered dose of ϳ10 mg/kg (abatacept 10/10), while the other group received a higher dose of abatacept for the first 5 infusions (30 mg/kg), followed by a fixed, weight-tiered dose of ϳ10 mg/kg every 28 days thereafter (abatacept 30/10). * Except for treatment failure, all other outcome measures required that the glucocorticoid dosage be tapered to Յ10 mg/day of prednisone (or equivalent). UPCR ϭ urine protein:creatinine ratio; RBCs ϭ red blood cells; WBCs ϭ white blood cells; eGFR ϭ estimated glomerular filtration rate.
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classification criteria for systemic lupus erythematosus, as defined by the American College of Rheumatology (6), and who had active, biopsy-proven class III or class IV lupus nephritis were randomly assigned 1:1:1 to 1 of 3 groups; 2 patients did not receive study medication. One group received placebo infusions on days 1, 15, and 29, and every 28 days thereafter for 12 months. A second group received abatacept infusions at a fixed, weight-tiered dose approximating 10 mg/kg according to the same schedule (abatacept 10/10). The third group received a higher dose of abatacept for the first 5 infusions (30 mg/kg), followed by a fixed, weight-tiered dose of ϳ10 mg/kg every 28 days (abatacept 30/10). All patients also received MMF and glucocorticoids throughout the trial. Oral glucocorticoids were initiated at a dosage equivalent to 30-60 mg/day of prednisone or prednisolone. A tapering regimen was recommended that was designed to reach a dosage of 10 mg/day by week 12 of treatment, but adherence to this regimen was not required if the site investigator deemed it not in the patient's best interest.
Comparison of outcome measures. Table 1 describes the outcome measures that were applied to the data set. The CR and PR criteria were obtained from the Lupus Nephritis Assessment of Rituximab (LUNAR) trial of rituximab for lupus nephritis (5) . Those criteria were chosen because the LUNAR definition of CR discriminated most clearly between treatment and control in our prior comparison of various CR definitions (1) . We also examined a closely related criterion, termed major clinical response (MCR). This possible alternative to CR was included to acknowledge that some of the "partial responses" observed in patients with very severe nephritis at baseline appeared to be at least as dramatic as some of the CRs in patients with mild disease at baseline.
Previous studies have shown that a 75% reduction in proteinuria correlates well with a favorable long-term outcome in patients with lupus nephritis (7) . Therefore, we used a reduction of at least 75% as the threshold for evaluating improvement in proteinuria. With regard to renal function, there are no data in the literature to provide a clear rationale for choosing a particular threshold for improvement, so we defined improvement in renal function somewhat arbitrarily as an increase of at least 25% in the estimated glomerular filtration rate (eGFR).
Finally, we also examined the time to CR and the frequency of treatment failure, as defined in Table 1 . For the purpose of these analyses, we based our definition of time to CR on the principle that the concept of time to CR is only meaningful for patients who maintained a status of CR through week 52 and not for patients in whom CR was evanescent. Therefore, the analysis of time to CR reflects only those patients who met the criteria for CR at week 52.
As noted above, the CR and PR criteria used in our analyses were drawn from the LUNAR trial. This trial required a urine protein:creatinine ratio (UPCR) of Ն1.0 for patient inclusion. Therefore, we limited our analyses to the subset of patients who met this entry criterion, which resulted in the following group sizes: control (n ϭ 80), abatacept 10/10 (n ϭ 87), and abatacept 30/10 (n ϭ 86).
Statistical analysis. Several methods were used to compare the various outcome measures. For each potential outcome measure, we determined 1) the 95% confidence interval around the observed difference in response rates between treatment and control; 2) the P value for betweengroup differences that would have been achieved (by Fisher's 2-tailed exact test) if that measure had been prespecified as the primary outcome measure; and 3) the group size that would have been required to achieve a P value less than 0.05 based on the actual data from the trial. Figure 1A shows the results at 52 weeks for the CR, total response (CR plus PR), and MCR in each Figure 2 . Frequency of improved urine protein:creatinine ratio (UPCR) (reduction in UPCR of Ն75%), improved estimated glomerular filtration rate (eGFR) (increase in eGFR of Ն25%), and treatment failure at week 52 in each abatacept treatment group (as described in Figure 1 ) compared with the standard-of-care placebo control group. Time to complete response (CR) among patients who met the CR criteria at week 52 in the abatacept treatment groups (as described in Figure 1 ) compared with the placebo control group. This outcome measure was based on the principle that the concept of time to CR is meaningful only for patients who maintained the CR status and not for those whose CR was evanescent. Therefore, only the data for the patients who met the CR criteria at week 52 are shown. Values below the plot are the number of patients evaluated at each time point. abatacept treatment group compared to the placebo control group. The magnitude of the difference between treatment and control was greater for the CR (4-fold) and MCR (2.5-fold) than it was for total response (CR plus PR) (1.5-fold). Figure 1B shows the performance of the same outcome measures at 24 weeks rather than 52 weeks. Similarly, at this earlier time point, the magnitude of the difference between treatment and control was greater for the CR and MCR (3-to 4-fold) than it was for total response (CR plus PR) (Ͻ1.5-fold). Figure 2 shows the results at week 52 for improvement in proteinuria (Ն75% reduction in the UPCR), improvement in the eGFR (Ն25% increase), and treatment failure. For each of these measures, the treatment groups fared better than the control group, but the magnitude of the difference between treatment and control was Ͻ2-fold. Much more striking was the result for time to CR (Figure 3) , which was considerably shorter in the treatment groups. We utilized several approaches to compare the relative performance of the various outcome measures. Table 2 shows the response rate data for each outcome Figure 3 for the data on time to complete response.
RESULTS
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measure, along with the 95% confidence intervals around the actual difference in response rates between each treatment group and the control group. Table 2 also shows the P value that would correspond to these differences if a particular measure had been prespecified as the primary outcome measure. Figure 4 shows the group sizes that would have been required to demonstrate a statistically significant difference between treatment and control if the measure had, in fact, been the prespecified outcome measure. By applying each of these approaches, we found that the CR at week 52, the MCR at week 52, and the time to CR were the primary outcome measures that best discriminated between treatment and control. The P values for comparison of both abatacept treatment groups with the control group were Ͻ0.004 for these 3 measures, and the 95% confidence intervals around the response rates for the 3 measures most clearly distinguished treatment from control. For each of these 3 primary outcome measures, group sizes of 50 patients would have been sufficient to demonstrate a statistically significant difference based on the observed response rates in the treatment and control groups. The other outcome measures were distinctly less effective at discriminating treatment from control. Their order, from most to least discriminating, and the approximate number of patients that would have been required to show statistical significance, was as follows: MCR at week 24 (80 per group), treatment failure at week 52 (90 per group), UPCR reduced by Ն75% at week 52 (90 per group), CR at week 24 (90 per group), total response at week 52 (100 per group), total response at week 24 (250 per group), and eGFR increased by Ն25% at week 52 (Ͼ500 per group) ( Figure  4 ).
DISCUSSION
The challenge of developing effective therapies for lupus nephritis is underscored by the fact that no drug has ever been approved for this indication. This challenge is compounded by the lack of direct evidence to guide us in determining what outcome measure might be most sensitive in detecting differences between treatment groups. The findings presented here suggest 2 tentative conclusions with regard to trial design. First, at least for the data that we evaluated, the implication is that CR rates are preferable to alternative outcome measures that have been used in previous lupus nephritis trials. Second, depending on the size of the trial, 6 months may not be sufficient to convincingly demonstrate efficacy; 1 year is likely to provide a clearer distinction between treatment and control.
The results of our analyses, and the conclusions summarized above, should be viewed with caution. These findings reflect the results of a single trial involving a single agent. Moreover, while additional trials of abatacept in lupus nephritis are under way, the results of this trial have yet to be replicated. Even if subsequent studies of abatacept confirm these results, it is possible that other agents might work more or less quickly, yield a different distribution between complete and partial responses, or even work through mechanisms that require different response criteria. Therefore, these analyses should be viewed as only one step toward building a stronger evidence base for the design of lupus nephritis trials.
Although it has become part of the lupus nephritis lexicon to refer to "complete" responses, it is not possible to distinguish clinically between true quiescence within the kidney and underlying subclinical activity. It is also the case that some abnormalities in renal function may be irreversible, precluding achievement of current definitions of CR; nonetheless, ongoing inflammation in the kidney may have been eradicated. Thus, concepts such as "complete response" or remission may not accurately reflect the true disease state. For this reason, we explored an alternative outcome measure, the MCR, which was designed to include the greatest clinical responses, without making assumptions about completeness. This outcome measure included not only patients who had met the CR criteria, but also patients who had nephrotic-range levels of proteinuria at baseline and whose UPCR subsequently improved to Ͻ1. Although this outcome measure performed as well as the CR definition, it did not significantly improve it.
Although the CR (or MCR) rates appear to be most sensitive in discriminating between groups in the short term (over 1 year), it remains to be determined whether this measure will correlate best with long-term outcome. In the final analysis, the goal is not achieved at 1 year in patients with lupus nephritis. Rather, it is achieved over many years, by preventing progressive renal insufficiency and end-stage renal disease. Past studies that focused on treatment failure as the outcome measure, such as the National Institutes of Health and Euro-Lupus trials of cyclophosphamide, chose a longer trial duration as a means of achieving a more compelling end point. The reality of drug-development timelines push us toward shorter trial designs and to suitable end points that fit these designs. Moreover, patients and physicians depend heavily on early measures of response to guide therapeutic decisions.
Nonetheless, long-term patient outcomes are the ones that matter most. In the absence of data on the long-term outcome among the patients in this trial, we cannot determine whether the superior sensitivity of the CR outcome measure will come at the expense of specificity in predicting long-term outcome. In this regard, it is reassuring that recent studies have shown a strong correlation between complete response and eventual patient and renal survival, as well as a correlation between poor early responses and poor patient and renal outcomes (8) . These studies suggest that complete responses not only may be more sensitive than other outcome measures in trials of modest length, but also may be a better measure for predicting long-term outcome.
